Comparative Study
doi: 10.1016/s0264-410x(00)00096-7.
Comparison of immunogenicity and reactogenicity of a measles, mumps and rubella (MMR) vaccine in German children vaccinated at 9-11, 12-14 or 15-17 months of age
Affiliations
- PMID: 10856793
- DOI: 10.1016/s0264-410x(00)00096-7
Item in Clipboard
Comparative Study
Comparison of immunogenicity and reactogenicity of a measles, mumps and rubella (MMR) vaccine in German children vaccinated at 9-11, 12-14 or 15-17 months of age
Vaccine.
.
Abstract
Children aged 9-11, 12-14 or 15-17 months, respectively were vaccinated with a measles, mumps and rubella (MMR) vaccine and serum antibody responses and reactogenicity were compared. The data of 118 children could be analysed (group 1=9-11 months, n=46; group 2=12-14 months, n=29, group 3, 15-17 months, n=43). The only significant difference observed was for seroconversion against measles virus between group 1 and group 3 (84.8% vs 100%, p=0.012). No serious adverse events were reported. Local side reactions were mild, infrequent and independent of age. Immunisation against MMR is safe and effective even when administered before the currently recommended age of 12 months.
Similar articles
-
Reactogenicity and immunogenicity of a new live attenuated combined measles, mumps and rubella vaccine in healthy children.Pediatr Infect Dis J. 1999 Jan;18(1):42-8. doi: 10.1097/00006454-199901000-00011. Pediatr Infect Dis J. 1999. PMID: 9951979 Clinical Trial.
-
Reactogenicity and immunogenicity of a new combined measles-mumps-rubella vaccine: results of a multicentre trial. The Cooperative Group for the Study of MMR vaccines.Vaccine. 2000 Jun 15;18(25):2796-803. doi: 10.1016/s0264-410x(00)00081-5. Vaccine. 2000. PMID: 10812221 Clinical Trial.
-
Seroconversion of a trivalent measles, mumps, and rubella vaccine in children aged 9 and 15 months.Vaccine. 1997 Dec;15(17-18):1898-901. doi: 10.1016/s0264-410x(97)00135-7. Vaccine. 1997. PMID: 9413099 Clinical Trial.
-
Vaccine-induced antibodies by commercial test kits, the case of the Rubini mumps and the Edmonston-Zagreb measles vaccine strains.Vaccine. 2000 Oct 15;19(4-5):396-8. doi: 10.1016/s0264-410x(00)00200-0. Vaccine. 2000. PMID: 11203403 Review. No abstract available.
-
Increase in congenital rubella occurrence after immunisation in Greece: retrospective survey and systematic review.BMJ. 1999 Dec 4;319(7223):1462-7. doi: 10.1136/bmj.319.7223.1462. BMJ. 1999. PMID: 10582926 Free PMC article.
Cited by
-
Modelling the first dose of measles vaccination: the role of maternal immunity, demographic factors, and delivery systems.Epidemiol Infect. 2011 Feb;139(2):265-74. doi: 10.1017/S0950268810001329. Epub 2010 Jun 7. Epidemiol Infect. 2011. PMID: 20525415 Free PMC article.
-
Post-immunisation fever and the antibody response to measles-containing vaccines.Epidemiol Infect. 2018 Sep;146(12):1584-1592. doi: 10.1017/S0950268818001474. Epub 2018 Jun 11. Epidemiol Infect. 2018. PMID: 29886856 Free PMC article.
-
Biomaterials for vaccine-based cancer immunotherapy.J Control Release. 2018 Dec 28;292:256-276. doi: 10.1016/j.jconrel.2018.10.008. Epub 2018 Oct 9. J Control Release. 2018. PMID: 30312721 Free PMC article. Review.
-
Differential immune responses to primary measles-mumps-rubella vaccination in Israeli children.Clin Diagn Lab Immunol. 2004 Sep;11(5):913-8. doi: 10.1128/CDLI.11.5.913-918.2004. Clin Diagn Lab Immunol. 2004. PMID: 15358652 Free PMC article.
-
Lower transplacental antibody transport for measles, mumps, rubella and varicella zoster in very preterm infants.PLoS One. 2014 Apr 11;9(4):e94714. doi: 10.1371/journal.pone.0094714. eCollection 2014. PLoS One. 2014. PMID: 24728480 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
